An article entitled "PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy" published online in the J Clin Invest indicates that PD-L1 in the tumor microenvironment mediates the resistance of tumor cells to oncolytic virus immunotherapy. It explains the mechanism of drug resistance of oncolytic virus therapy and provides a direction for further optimization of oncolytic virus therapy.
This research was highly evaluated in a special comment entitled Unleashing the therapeutic potential of oncolytic viruses, which was published in the same issue of J Clin Invest.
1.J Clin Invest. 2018 Apr 2;128(4):1413-1428. doi: 10.1172/JCI98047
2.J Clin Invest. 2018;128(4):1258-1260.. https://doi.org/10.1172/JCI120303